Renal denervation mitigates cardiac remodeling and renal damage in Dahl rats: A comparison with β-receptor blockade

Hypertension Research

Volumn 39, Issue 4, 2016, Pages 217-226

  Watanabe, Heitaro ^a   Iwanaga, Yoshitaka ^a   Miyaji, Yuki ^a   Yamamoto, Hiromi ^a   Miyazaki, Shunichi ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

cardiorenal syndrome; heart failure; renal denervation; sympathetic nervous system; receptor blockade

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD CHEMISTRY; BLOOD PRESSURE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG EFFECT; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RATE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOLOGY; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MEAN ARTERIAL PRESSURE; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; SHAM PROCEDURE; SURVIVAL TIME; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; URINE CHEMISTRY; WESTERN BLOTTING; ANIMAL; CARDIAC MUSCLE; DAHL RAT; DENERVATION; DRUG EFFECTS; HYPERTROPHY, LEFT VENTRICULAR; INNERVATION; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYMPATHECTOMY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BISOPROLOL; BLOOD PRESSURE; DENERVATION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; KIDNEY DISEASES; MALE; MYOCARDIUM; RATS; RATS, INBRED DAHL; RECEPTORS, ADRENERGIC, BETA-1; SYMPATHECTOMY; TYROSINE 3-MONOOXYGENASE;

EID: 84962753920     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.133     Document Type: Article

References (38)

1. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999; 341: 577-585
2. Barrese V, Taglialatela M. New advances in beta-blocker therapy in heart failure. Front Physiol 2013; 4: 323
3. Singh JP, Kandala J, Camm AJ. Non-pharmacological modulation of the autonomic tone to treat heart failure. Eur Heart J 2014; 35: 77-85
4. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539
5. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, De Zeeuw D, Pocock S, Van Veldhuisen DJCandesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678
6. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
7. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R245-R253
8. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GLSYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401
9. Nagasu H, Satoh M, Kuwabara A, Yorimitsu D, Sakuta T, Tomita N, Kashihara N. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant 2010; 25: 2889-2898
10. Jensen BC, O?Connell TD, Simpson PC. Alpha-1-Adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation. J Cardiovasc Pharmacol 2014; 63: 291-301
11. Baker AJ. Adrenergic signaling in heart failure: A balance of toxic and protective effect. Pflugers Arch 2014; 466: 1139-1150
12. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol 1994; 267: H2471-H2482
13. Pires NM, Igreja B, Moura E, Wright LC, Serrão MP, Soares-da-Silva P. Blood pressure decrease in spontaneously hypertensive rats following renal denervation or dopamine ?-hydroxylase inhibition with etamicastat. Hypertens Res 2015; 38: 605-612
14. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-Angiotensin type 1 receptor system. J Mol Cell Cardiol 2006; 41: 798-806
15. Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004; 113: 727-736
16. Adhikary LP, Yamamoto T, Isome M, Nakano Y, Kawasaki K, Yaoita E, Kihara I. Expression profile of extracellular matrix and its regulatory proteins during the process of interstitial fibrosis after antiglomerular basement membrane antibody-induced glomerular sclerosis in Sprague-Dawley rats. Pathol Int 1999; 49: 716-725
17. Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R, Ferrari AU. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 2005; 46: 1213-1218
18. Osborn JL, Roman RJ, Ewens JD. Renal nerves and the development of Dahl saltsensitive hypertension. Hypertension 1988; 11: 523-528
19. Foss JD, Fink GD, Osborn JW. Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension 2013; 61: 806-811
20. Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. Hypertension 1995; 26: 808-814
21. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DLSYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol 2014; 64: 1071-1078
22. Schiller AM, Haack KK, Pellegrino PR, Curry PL, Zucker IH. Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure. Am J Physiol Regul Integr Comp Physiol 2013; 305: R886-R892
23. Hu J, Yan Y, Zhou Q, Ji M, Niu C, Hou Y, Ge J. Effects of renal denervation on the development of post-myocardial infarction heart failure and cardiac autonomic nervous system in rats. Int J Cardiol 2014; 172: e414-e416
24. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001; 22: 1136-1143
25. Malpas SC. Sympathetic nervous systemoveractivity and its role in the development of cardiovascular disease. Physiol Rev 2010; 90: 513-557
26. Linz D, Hohl M, Schütze J, Mahfoud F, Speer T, Linz B, Hübschle T, Juretschke HP, Dechend R, Geisel J, Rütten H, Böhm M. Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: the role of renal sympathetic innervation. Am J Hypertens 2015; 28: 256-265
27. Eriguchi M, Tsuruya K, Haruyama N, Yamada S, Tanaka S, Suehiro T, Noguchi H, Masutani K, Torisu K, Kitazono T. Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. Kidney Int 2015; 87: 116-127
28. Nagatsu M, Spinale FG, Koide M, Tagawa H, DeFreitas G, Cooper G 4th, Carabello BA. Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation 2000; 101: 653-659
29. Yamakawa H, Takeuchi M, Takaoka H, Hata K, Mori M, Yokoyama M. Negative chronotropic effect of beta-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. Circulation 1996; 94: 340-345
30. McCloskey DT, Turnbull L, Swigart P, O'Connell TD, Simpson PC, Baker AJ. Abnormal myocardial contraction in alpha(1A)- and alpha(1B)-Adrenoceptor doubleknockout mice. J Mol Cell Cardiol 2003; 35: 1207-1216
31. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, Lohse MJ, Hein L. Feedback inhibition of catecholamine release by two different alpha2- adrenoceptor subtypes prevents progression of heart failure. Circulation 2002; 106: 2491-2496
32. Aggarwal A, Esler MD, Socratous F, Kaye DM. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol 2001; 37: 1246-1251
33. DiBona GF. Neural control of renal function: cardiovascular implications. Hypertension 1989; 13: 539-548
34. Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 2011; 300: F31-F39
35. Kim J, Padanilam BJ. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol 2013; 24: 229-242
36. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol 1980; 238: R353-R358
37. Reddy VY, Olin JW. Renal denervation for resistant hypertension: not dead yet. J Am Coll Cardiol 2014; 64: 1088-1091
38. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909